Insights - PropThink published an ASCO 2014 preview early this week, highlighting events that will capture Wall Street’s interest as abstracts are published online and presentations kick off at … Continue Reading
Read NowRecap - We count at least nine failures of one sort or another (Complete Response Letters, failed trials) in the last five days from companies such as Pozen (POZN), … Continue Reading
Read NowRecap - An update from Sarepta Therapeutics (SRPT) first thing on Monday morning caught the attention of the biotech world – and sent one of our 2014 recommendations to PropThink Premium … Continue Reading
Read NowInsights - The situation gets interesting next week for the biotech sector. Here’s why: A sentiment-shift in relation to biotech. We’re getting into the heart of earnings … Continue Reading
Read NowRecap - Neptune Technologies (NEPT) was one of a few green equities in a sea of red on Friday. Why? Some of NEPT’s largest shareholders, a crowd with a history of activism, … Continue Reading
Read NowRecap - Continued weakness in the healthcare sector this week was marked on Friday by the iShares Biotech Index’s (IBB) break of a key uptrend and support level, suggesting … Continue Reading
Read NowRecap - The S&P 500 and the NASDAQ ended the Friday trading session in the green, both nearly flat year-to-date, while the biotech sector continued sliding lower … Continue Reading
Read Now